Published • loading... • Updated
Curium Inks Definitive Deal to Acquire Radiopharma Rival Lantheus for up to $8B
The deal pairs Curium’s global theranostics platform with Lantheus’s U.S. radiodiagnostics business and gives shareholders up to $114.50 per share.
- On Monday, Curium announced a definitive agreement to acquire Lantheus for up to $8.0 billion, combining their radiopharmaceutical portfolios in a strategic merger.
- The merger unites Curium's "theranostics" portfolio with Lantheus' complementary radiodiagnostics business, creating a combined company serving patients across more than 70 countries.
- Lantheus shareholders will receive $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights providing up to $12 per share if sales milestones are achieved by 2030.
- Renaud Dehareng, Curium chief executive, said "Lantheus is the ideal partner to accelerate what we have been building," citing complementary prostate cancer detection products.
- Expected to close in the first half of 2027, the combined entity will expand into oncology, neurology, and cardiology markets while leveraging integrated global manufacturing capabilities.
Insights by Ground AI
17 Articles
17 Articles
The blockbuster potential of radiopharmaceuticals is drawing bigger bets.
·Arlington, United States
Read Full Article
Lantheus Holdings agreed to be purchased by Curium, a competing company in the radiopharmaceutical sector controlled by CapWest Partners, in an initial transaction valued at $6.7 billion. Exclusive to subscribers. To have full access, access the material link and register.
·Rio de Janeiro, Brazil
Read Full Article
The American group Curium Pharma, based in Boston, wants to get hold of its rival Lantheus. ...
·Brussels, Belgium
Read Full ArticleCoverage Details
Total News Sources17
Leaning Left4Leaning Right2Center8Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 29%
C 57%
14%
Factuality
To view factuality data please Upgrade to Premium
